Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (256) 256
Publication (30) 30
Book Chapter (23) 23
Report (10) 10
Book / eBook (4) 4
Patent (4) 4
Book Review (3) 3
Dissertation (3) 3
Conference Proceeding (1) 1
Newspaper Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (140) 140
male (108) 108
oncology (70) 70
middle aged (64) 64
female (62) 62
aged (60) 60
index medicus (60) 60
adult (45) 45
chemotherapy (43) 43
cancer (42) 42
treatment outcome (35) 35
canada (33) 33
aged, 80 and over (30) 30
drug therapy (30) 30
antineoplastic combined chemotherapy protocols - therapeutic use (27) 27
urology & nephrology (25) 25
clinical trials as topic (23) 23
antineoplastic agents - therapeutic use (22) 22
care and treatment (22) 22
clinical trials (21) 21
cisplatin (20) 20
randomized controlled trials as topic (20) 20
research (19) 19
disease-free survival (18) 18
survival analysis (18) 18
therapy (18) 18
antineoplastic combined chemotherapy protocols - adverse effects (17) 17
medicine & public health (17) 17
metastasis (17) 17
prognosis (17) 17
prostate cancer (17) 17
antineoplastic agents - adverse effects (15) 15
carcinoma (15) 15
neoplasm staging (15) 15
prostatic neoplasms - therapy (15) 15
radiotherapy (15) 15
carcinoma, transitional cell - drug therapy (14) 14
cisplatin - administration & dosage (14) 14
quality of life (14) 14
survival (14) 14
trial (14) 14
urinary bladder neoplasms - drug therapy (14) 14
diagnosis (13) 13
pharmacology & pharmacy (13) 13
retrospective studies (13) 13
combined modality therapy (12) 12
dosage and administration (12) 12
head and neck neoplasms - drug therapy (12) 12
prostatic neoplasms - drug therapy (12) 12
cancer therapies (11) 11
docetaxel (11) 11
follow-up studies (11) 11
neoplasm metastasis (11) 11
parent participation (11) 11
patient outcomes (11) 11
pharmacology/toxicology (11) 11
squamous cell carcinoma (11) 11
academic achievement (10) 10
analysis (10) 10
carcinoma, squamous cell - drug therapy (10) 10
disease progression (10) 10
kidney neoplasms - drug therapy (10) 10
patients (10) 10
surgery (10) 10
antimitotic agents (9) 9
antineoplastic agents (9) 9
drug administration schedule (9) 9
health aspects (9) 9
medical research (9) 9
original research (9) 9
phase-iii trial (9) 9
prostatic neoplasms (9) 9
randomized-trial (9) 9
squamous-cell carcinoma (9) 9
time factors (9) 9
urologic neoplasms - therapy (9) 9
abridged index medicus (8) 8
carcinoma, squamous cell - mortality (8) 8
carcinoma, transitional cell - pathology (8) 8
elementary secondary education (8) 8
gemcitabine (8) 8
head and neck cancer (8) 8
head and neck neoplasms - mortality (8) 8
head and neck neoplasms - pathology (8) 8
hematology, oncology and palliative medicine (8) 8
medicine, experimental (8) 8
parent school relationship (8) 8
proportional hazards models (8) 8
risk factors (8) 8
survival rate (8) 8
urinary bladder neoplasms - pathology (8) 8
urinary bladder neoplasms - therapy (8) 8
vinblastine (8) 8
abiraterone acetate (7) 7
comparative analysis (7) 7
complications and side effects (7) 7
cooperative-oncology-group (7) 7
deoxycytidine - administration & dosage (7) 7
deoxycytidine - analogs & derivatives (7) 7
expression (7) 7
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text Editorial Comment
by Winquist, Eric
Journal of Urology, ISSN 0022-5347, 08/2018, Volume 200, Issue 2, pp. 351 - 352
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Editorial Comment
by Winquist, Eric
The Journal of Urology, ISSN 0022-5347, 08/2018, Volume 200, Issue 2, pp. 351 - 352
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Editorial Comment
by Winquist, Eric
Journal of Urology, ISSN 0022-5347, 08/2018, Volume 200, Issue 2, pp. 351 - 352
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
by Ryan, Charles J and Smith, Matthew R and de Bono, Johann S and Molina, Arturo and Logothetis, Christopher J and de Souza, Paul and Fizazi, Karim and Mainwaring, Paul and Piulats, Josep M and Ng, Siobhan and Carles, Joan and Mulders, Peter F.A and Basch, Ethan and Small, Eric J and Saad, Fred and Schrijvers, Dirk and Van Poppel, Hendrik and Mukherjee, Som D and Suttmann, Henrik and Gerritsen, Winald R and Flaig, Thomas W and George, Daniel J and Yu, Evan Y and Efstathiou, Eleni and Pantuck, Allan and Winquist, Eric and Higano, Celestia S and Taplin, Mary-Ellen and Park, Youn and Kheoh, Thian and Griffin, Thomas and Scher, Howard I and Rathkopf, Dana E and COU-AA-302 Investigators
The New England Journal of Medicine, ISSN 0028-4793, 01/2013, Volume 368, Issue 2, pp. 138 - 148
Abiraterone has been approved as second-line chemotherapy in patients with metastatic castration-resistant prostate cancer. This study shows significant... 
HUMAN CYTOCHROME P450(17-ALPHA) | CONTROLLED-TRIAL | MEDICINE, GENERAL & INTERNAL | PREDNISONE | MITOXANTRONE | INHIBITION | END-POINTS | CYP17 | ACETATE | DOCETAXEL | HORMONAL-THERAPY | Prednisone - adverse effects | Double-Blind Method | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Abiraterone Acetate | Prostatic Neoplasms - mortality | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Neoplasm Metastasis | Prostatic Neoplasms - secondary | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Antineoplastic Agents, Hormonal - therapeutic use | Survival Analysis | Androstadienes - therapeutic use | Androstadienes - adverse effects | Prednisone - therapeutic use | Prostatic Neoplasms - drug therapy | Drugs | Dose-response relationship (Biochemistry) | Chemotherapy | Usage | Care and treatment | Patient outcomes | Product/Service Evaluations | Drug therapy | Prostate cancer | Cancer | Clinical trials | Cancer therapies | Regulatory approval | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial
by Nichols, Anthony C and Theurer, Julie and Prisman, Eitan and Read, Nancy and Berthelet, Eric and Tran, Eric and Fung, Kevin and de Almeida, John R and Bayley, Andrew and Goldstein, David P and Hier, Michael and Sultanem, Khalil and Richardson, Keith and Mlynarek, Alex and Krishnan, Suren and Le, Hien and Yoo, John and MacNeil, S Danielle and Winquist, Eric and Hammond, J Alex and Venkatesan, Varagur and Kuruvilla, Sara and Warner, Andrew and Mitchell, Sylvia and Chen, Jeff and Corsten, Martin and Johnson-Obaseki, Stephanie and Eapen, Libni and Odell, Michael and Parker, Christina and Wehrli, Bret and Kwan, Keith and Palma, David A
The Lancet Oncology, ISSN 1470-2045, 10/2019, Volume 20, Issue 10, pp. 1349 - 1359
Transoral robotic surgery (TORS) with concurrent neck dissection has supplanted radiotherapy in the USA as the most common treatment for oropharyngeal squamous... 
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text Effect of Selenium and Vitamin E on Risk of Prostate Cancer and Other Cancers: The Selenium and Vitamin E Cancer Prevention Trial (SELECT)
by Lippman, Scott M and Klein, Eric A and Goodman, Phyllis J and Lucia, M. Scott and Thompson, Ian M and Ford, Leslie G and Parnes, Howard L and Minasian, Lori M and Gaziano, J. Michael and Hartline, Jo Ann and Parsons, J. Kellogg and Bearden, James D and Crawford, E. David and Goodman, Gary E and Claudio, Jaime and Winquist, Eric and Cook, Elise D and Karp, Daniel D and Walther, Philip and Lieber, Michael M and Kristal, Alan R and Darke, Amy K and Arnold, Kathryn B and Ganz, Patricia A and Santella, Regina M and Albanes, Demetrius and Taylor, Philip R and Probstfield, Jeffrey L and Jagpal, T. J and Crowley, John J and Meyskens, Frank L and Baker, Laurence H and Coltman, Charles A
JAMA, ISSN 0098-7484, 01/2009, Volume 301, Issue 1, pp. 39 - 51
CONTEXT Secondary analyses of 2 randomized controlled trials and supportive epidemiologic and preclinical data indicated the potential of selenium and vitamin... 
BREAST-CANCER | SUPPLEMENTATION | MORTALITY | MEDICINE, GENERAL & INTERNAL | BETA-CAROTENE | NUTRITIONAL PREVENTION | CARDIOVASCULAR-DISEASE | ALPHA-TOCOPHEROL | RANDOMIZED CONTROLLED-TRIAL | CELL-LINES | CARCINOMA | Double-Blind Method | Humans | Middle Aged | Male | Neoplasms - prevention & control | Treatment Outcome | Prostatic Neoplasms - epidemiology | Selenomethionine - therapeutic use | Selenium - therapeutic use | alpha-Tocopherol - therapeutic use | Antioxidants - therapeutic use | Vitamin E - therapeutic use | Aged | Prostatic Neoplasms - prevention & control | Dietary Supplements | Neoplasms - epidemiology | Disease prevention | Clinical trials | Selenium | Vitamin E | Prostate cancer | Risk factors | Index Medicus | Abridged Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text The “Dirty Harry” Approach
by Bauman, Glenn and Winquist, Eric
International Journal of Radiation Oncology, Biology, Physics, ISSN 0360-3016, 09/2017, Volume 99, Issue 1, pp. 8 - 8
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text Editorial Comment
by Winquist, Eric
The Journal of urology, 08/2018, Volume 200, Issue 2, p. 351
Prostate-Specific Antigen | Prostatic Neoplasms, Castration-Resistant | Humans | Male | Prednisone | Abiraterone Acetate | Disease Progression
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial
by Vermorken, Jan B, Dr and Stöhlmacher-Williams, Jan, MD and Davidenko, Irina, MD and Licitra, Lisa, MD and Winquist, Eric, MD and Villanueva, Cristian, MD and Foa, Paolo, MD and Rottey, Sylvie, MD and Skladowski, Krzysztof, MD and Tahara, Makoto, MD and Pai, Vasant R, MD and Faivre, Sandrine, MD and Blajman, Cesar R, MD and Forastiere, Arlene A, MD and Stein, Brian N, MBBS and Oliner, Kelly S, PhD and Pan, Zhiying, PhD and Bach, Bruce A, MD and SPECTRUM Investigators and SPECTRUM investigators
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 697 - 710
Summary Background Previous trials have shown that anti-EGFR monoclonal antibodies can improve clinical outcomes of patients with recurrent or metastatic... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | P16 | ONCOLOGY | COLORECTAL-CANCER | OROPHARYNGEAL CANCER | HUMAN-PAPILLOMAVIRUS | P16(INK4A) | SUBSET | III TRIAL | COOPERATIVE-ONCOLOGY-GROUP | PLUS FLUOROURACIL | Immunohistochemistry | South America | Head and Neck Neoplasms - virology | Prospective Studies | Carcinoma, Squamous Cell - virology | Humans | Middle Aged | Neoplasm Recurrence, Local - virology | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Neoplasm Recurrence, Local - drug therapy | Male | North America | Cisplatin - administration & dosage | Neoplasm Recurrence, Local - pathology | Head and Neck Neoplasms - chemistry | Neoplasm Metastasis | Carcinoma, Squamous Cell - mortality | Cyclin-Dependent Kinase Inhibitor p16 - analysis | Fluorouracil - administration & dosage | Time Factors | Female | Retrospective Studies | Biomarkers, Tumor - analysis | Europe | Head and Neck Neoplasms - drug therapy | Kaplan-Meier Estimate | Proportional Hazards Models | Carcinoma, Squamous Cell - chemistry | Treatment Outcome | Papillomaviridae - isolation & purification | Neoplasm Recurrence, Local - chemistry | Head and Neck Neoplasms - pathology | Disease-Free Survival | Carcinoma, Squamous Cell - drug therapy | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Asia | Biopsy | Carcinoma, Squamous Cell - secondary | Aged | Head and Neck Neoplasms - mortality | Care and treatment | Relapse | Carcinoma | Monoclonal antibodies | Product development | Metastasis | Cisplatin | Cancer | Diseases | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Phase II Trial of Sorafenib in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck or Nasopharyngeal Carcinoma
by Christine Elser and Lillian L. Siu and Eric Winquist and Mark Agulnik and Gregory R. Pond and Soo F. Chin and Peggy Francis and Robin Cheiken and James Elting and Angela McNabola and Dean Wilkie and Oana Petrenciuc and Eric X. Chen
Journal of Clinical Oncology, ISSN 0732-183X, 08/2007, Volume 25, Issue 24, pp. 3766 - 3773
Purpose To determine the efficacy and safety of single- agent sorafenib in patients with recurrent and/ or metastatic squamous cell carcinoma of the head and... 
GROWTH-FACTOR RECEPTOR | BRAF GENE | PROGNOSTIC-FACTORS | SOLID TUMORS | ONCOLOGY | CLINICAL-TRIALS | PLATINUM-BASED CHEMOTHERAPY | TUMOR ANGIOGENESIS | CISPLATIN PLUS FLUOROURACIL | ANTIBODY CETUXIMAB | COOPERATIVE-ONCOLOGY-GROUP | Niacinamide - analogs & derivatives | Nasopharyngeal Neoplasms - mortality | raf Kinases - antagonists & inhibitors | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Nasopharyngeal Neoplasms - pathology | Carcinoma, Squamous Cell - mortality | Adult | Female | Nasopharyngeal Neoplasms - drug therapy | Pyridines - therapeutic use | Head and Neck Neoplasms - drug therapy | Neoplasm Recurrence, Local | Survival Rate | Disease Progression | Head and Neck Neoplasms - pathology | Disease-Free Survival | Carcinoma, Squamous Cell - drug therapy | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Squamous Cell - secondary | Aged | Head and Neck Neoplasms - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Imatinib Mesylate in Patients With Adenoid Cystic Cancers of the Salivary Glands Expressing c-kit: A Princess Margaret Hospital Phase II Consortium Study
by Sébastien J. Hotte and Eric W. Winquist and Elizabeth Lamont and Mary MacKenzie and Everett Vokes and Eric X. Chen and Shirley Brown and Gregory R. Pond and Anthony Murgo and Lillian L. Siu
Journal of Clinical Oncology, ISSN 0732-183X, 01/2005, Volume 23, Issue 3, pp. 585 - 590
Purpose This study aimed to assess the antitumor activity of imatinib in adenoid cystic carcinoma (ACC) of the salivary gland expressing c-kit. A high level of... 
HEAD | PROTEIN | CISPLATIN | ONCOLOGY | DISEASE | MALIGNANCIES | MUTATIONS | NECK | GASTROINTESTINAL STROMAL TUMORS | CARCINOMA | Immunohistochemistry | Salivary Gland Neoplasms - genetics | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Proto-Oncogene Proteins c-kit - biosynthesis | Antineoplastic Agents - adverse effects | Adult | Female | Proto-Oncogene Proteins c-kit - genetics | Antineoplastic Agents - pharmacology | Carcinoma, Adenoid Cystic - drug therapy | Carcinoma, Adenoid Cystic - pathology | Administration, Oral | Biomarkers, Tumor - analysis | Treatment Outcome | Piperazines - therapeutic use | Pyrimidines - pharmacology | Imatinib Mesylate | Piperazines - adverse effects | Piperazines - pharmacology | Salivary Gland Neoplasms - drug therapy | Carcinoma, Adenoid Cystic - genetics | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Survival Analysis | Aged | Benzamides | Salivary Gland Neoplasms - pathology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Nanoparticle albumin-bound paclitaxel for second-line treatment of metastatic urothelial carcinoma: a single group, multicentre, phase 2 study
by Ko, Yoo-Joung, Dr and Canil, Christine M, MD and Mukherjee, Som D, MD and Winquist, Eric, Prof and Elser, Christine, MD and Eisen, Andrea, MD and Reaume, M Neil, MD and Zhang, Liying, PhD and Sridhar, Srikala S, MD
Lancet Oncology, The, ISSN 1470-2045, 2013, Volume 14, Issue 8, pp. 769 - 776
Summary Background No standard treatment exists for patients with platinum-refractory urothelial cancer. Taxanes and vinflunine are commonly used, but response... 
Hematology, Oncology and Palliative Medicine | SPARC | CISPLATIN | ONCOLOGY | NAB-PACLITAXEL | TRANSITIONAL-CELL CARCINOMA | RANDOMIZED-TRIAL | OPEN-LABEL | II TRIAL | CANCER | DOCETAXEL | GEMCITABINE | Albumins - chemistry | Albumin-Bound Paclitaxel | Humans | Middle Aged | Ureteral Neoplasms - pathology | Male | Drug Carriers - chemistry | Urothelium - pathology | Nanoparticles | Ureteral Neoplasms - drug therapy | Paclitaxel - chemistry | Antineoplastic Agents, Phytogenic - administration & dosage | Albumins - adverse effects | Time Factors | Urinary Bladder Neoplasms - pathology | Aged, 80 and over | Adult | Female | Paclitaxel - administration & dosage | Antineoplastic Agents, Phytogenic - adverse effects | Carcinoma - secondary | Carcinoma - drug therapy | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Paclitaxel - adverse effects | Albumins - administration & dosage | Antineoplastic Agents, Phytogenic - chemistry | Treatment Outcome | Urinary Bladder Neoplasms - drug therapy | Chemistry, Pharmaceutical | Canada | Disease-Free Survival | Administration, Intravenous | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Urothelium - drug effects | Antimitotic agents | Care and treatment | Albumin | Metastasis | Drug therapy | Antineoplastic agents | Cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text Phase II Study of Lapatinib in Recurrent or Metastatic Epidermal Growth Factor Receptor and/or erbB2 Expressing Adenoid Cystic Carcinoma and Non–Adenoid Cystic Carcinoma Malignant Tumors of the Salivary Glands
by Mark Agulnik and Ezra W.E. Cohen and Roger B. Cohen and Eric X. Chen and Everett E. Vokes and Sebastien J. Hotte and Eric Winquist and Scott Laurie and D. Neil Hayes and Janet E. Dancey and Shirley Brown and Gregory R. Pond and Ian Lorimer and Manijeh Daneshmand and James Ho and Ming-Sound Tsao and Lillian L. Siu
Journal of Clinical Oncology, ISSN 0732-183X, 09/2007, Volume 25, Issue 25, pp. 3978 - 3984
Purpose Expression of erbB2 and/or epidermal growth factor receptor (EGFR) is associated with biologic aggressiveness and poor prognosis in malignant salivary... 
TRIAL | PROTEIN | CELL NUCLEAR ANTIGEN | SOLID TUMORS | ONCOLOGY | DUCT CARCINOMA | HER-2/NEU | KINASE INHIBITOR | C-ERBB-2 ONCOPROTEIN | CANCER | IMATINIB MESYLATE | Follow-Up Studies | Humans | Middle Aged | Neoplasm Recurrence, Local - drug therapy | Male | Adaptor Proteins, Signal Transducing - antagonists & inhibitors | Salivary Gland Neoplasms - metabolism | Aged, 80 and over | Biomarkers, Tumor - metabolism | Adult | Carcinoma, Adenoid Cystic - secondary | Female | Lapatinib | Carcinoma, Adenoid Cystic - drug therapy | Carcinoma, Adenoid Cystic - pathology | Neoplasm Recurrence, Local - metabolism | Carcinoma, Adenoid Cystic - metabolism | Epidermal Growth Factor - metabolism | Treatment Outcome | Disease-Free Survival | Salivary Gland Neoplasms - drug therapy | Quinazolines - therapeutic use | Epidermal Growth Factor - antagonists & inhibitors | Aged | Adaptor Proteins, Signal Transducing - metabolism | Salivary Gland Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text Phase I/II Trial of Erlotinib and Cisplatin in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: A Princess Margaret Hospital Phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study
by Lillian L. Siu and Denis Soulieres and Eric X. Chen and Gregory R. Pond and Soo F. Chin and Peggy Francis and Luc Harvey and Meri Klein and Wenjiang Zhang and Janet Dancey and Elizabeth A. Eisenhauer and Eric Winquist and National Cancer Institute of Canada Clinical Trials Group Study and Princess Margaret Hospital Phase II Consortium
Journal of Clinical Oncology, ISSN 0732-183X, 06/2007, Volume 25, Issue 16, pp. 2178 - 2183
Purpose To determine the phase II dose and objective response rate of erlotinib, a selective epidermal growth factor receptor tyrosine kinase inhibitor, in... 
LUNG-CANCER | MULTICENTER | CARCINOGENESIS | OSI-774 | ONCOLOGY | TYROSINE KINASE INHIBITOR | ANTIBODY CETUXIMAB | CHEMOTHERAPY | COOPERATIVE-ONCOLOGY-GROUP | PLUS FLUOROURACIL | PACLITAXEL | Erlotinib Hydrochloride | Humans | Middle Aged | Head and Neck Neoplasms - drug therapy | Quinazolines - pharmacokinetics | Male | Cisplatin - administration & dosage | Carcinoma, Squamous Cell - drug therapy | Carcinoma, Squamous Cell - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Quinazolines - adverse effects | Aged, 80 and over | Cisplatin - adverse effects | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adult | Female | Quinazolines - administration & dosage | Aged | Head and Neck Neoplasms - mortality
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
15. Full Text Exemestane for Breast-Cancer Prevention in Postmenopausal Women
by Goss, Paul E and Ingle, James N and Alés-Martínez, José E and Cheung, Angela M and Chlebowski, Rowan T and Wactawski-Wende, Jean and McTiernan, Anne and Robbins, John and Johnson, Karen C and Martin, Lisa W and Winquist, Eric and Sarto, Gloria E and Garber, Judy E and Fabian, Carol J and Pujol, Pascal and Maunsell, Elizabeth and Farmer, Patricia and Gelmon, Karen A and Tu, Dongsheng and Richardson, Harriet and NCIC CTG MAP 3 Study Investigators and NCIC CTG MAP.3 Study Investigators
The New England Journal of Medicine, ISSN 0028-4793, 06/2011, Volume 364, Issue 25, pp. 2381 - 2391
In postmenopausal women at increased risk for breast cancer, exemestane reduced the annual incidence of invasive breast cancer by 65% after a median follow-up... 
PHARMACOLOGICAL INTERVENTIONS | MEDICINE, GENERAL & INTERNAL | NONSTEROIDAL AROMATASE INHIBITORS | BONE-MINERAL DENSITY | RALOXIFENE | INCLUDING TAMOXIFEN | LETROZOLE | RANDOMIZED-TRIAL | RISK | QUALITY-OF-LIFE | AMERICAN-SOCIETY | Double-Blind Method | Follow-Up Studies | Neoplasm Invasiveness | Humans | Middle Aged | Risk Factors | Breast Neoplasms - prevention & control | Incidence | Aromatase Inhibitors - adverse effects | Aged, 80 and over | Postmenopause | Quality of Life | Adult | Female | Aged | Androstadienes - therapeutic use | Carcinoma, Intraductal, Noninfiltrating - epidemiology | Androstadienes - adverse effects | Aromatase Inhibitors - therapeutic use | Breast Neoplasms - epidemiology | Carcinoma, Intraductal, Noninfiltrating - prevention & control | Analysis | Breast cancer | Postmenopausal women | Diagnosis | Drug therapy | Health aspects | Risk factors | Quality of life | Endometrial cancer | Invasiveness | Hyperplasia | Menopause | Estrogen | Estrogen receptors | Clinical trials | Cardiovascular disease | Mammography | Tamoxifen | Patients | Post-menopause | Disease prevention | Fractures | Womens health | Aromatase | Raloxifene | Health risk assessment | Age | Index Medicus | Abridged Index Medicus | Càncer de mama | Testosterone | Ús terapèutic | Testosterona | Therapeutic use
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
16. Full Text Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987
by Joaquim Bellmunt and Hans von der Maase and Graham M. Mead and Iwona Skoneczna and Maria De Santis and Gedske Daugaard and Andreas Boehle and Christine Chevreau and Luis Paz-Ares and Leslie R. Laufman and Eric Winquist and Derek Raghavan and Sandrine Marreaud and Sandra Collette and Richard Sylvester and Ronald de Wit
Journal of Clinical Oncology, ISSN 0732-183X, 04/2012, Volume 30, Issue 10, pp. 1107 - 1113
textabstractPurpose: The combination of gemcitabine plus cisplatin (GC) is a standard regimen in patients with locally advanced or metastatic urothelial... 
TRIAL | BLADDER-CANCER | TRANSITIONAL-CELL-CARCINOMA | COLONY-STIMULATING FACTOR | PROGNOSTIC-FACTORS | TUMOR LOCATION | CISPLATIN | ONCOLOGY | MICROSATELLITE INSTABILITY | URINARY-TRACT | COOPERATIVE-ONCOLOGY-GROUP | Humans | Middle Aged | Carcinoma, Transitional Cell - secondary | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Urothelium - pathology | Cisplatin - administration & dosage | Urologic Neoplasms - pathology | Urologic Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Neutropenia - chemically induced | Paclitaxel - administration & dosage | Drug Administration Schedule | Deoxycytidine - administration & dosage | Treatment Outcome | Thrombocytopenia - chemically induced | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Carcinoma, Transitional Cell - drug therapy | Survival Analysis | Aged | Hemorrhage - chemically induced | Deoxycytidine - analogs & derivatives | Original Reports
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights